21 Participants Needed

CARv3-TEAM-E T Cells for Glioblastoma

WC
Overseen ByWilliam Curry, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).

Do I need to stop taking my current medications for the trial?

Participants must stop taking certain medications before joining the trial. Specifically, they need to be 4 weeks from their last dose of alkylating therapy or immunotherapy and must wait for at least 5 half-lives from another investigational agent. However, no washout period is required for radiation therapy.

What data supports the effectiveness of the CARv3-TEAM-E T Cells treatment for glioblastoma?

Research shows that CAR T-cell therapy, which involves modifying a patient's own T cells to better target cancer cells, has shown promise in treating glioblastoma by activating the immune system and potentially improving the tumor environment. Although still in early stages, studies have observed some signs of effectiveness in patients with glioblastoma, suggesting that this approach could help in fighting this challenging cancer.12345

Is CARv3-TEAM-E T Cells therapy safe for humans?

CAR T-cell therapy, including versions like CARv3-TEAM-E T Cells, has shown feasibility and safety in clinical studies for glioblastoma, although it can create an immunosuppressive environment in the brain.13678

How is the CARv3-TEAM-E T Cells treatment different from other treatments for glioblastoma?

The CARv3-TEAM-E T Cells treatment is unique because it uses genetically modified T cells to specifically target and attack glioblastoma cells, potentially overcoming the challenges of the tumor's location and immune evasion. This approach is different from traditional treatments as it aims to enhance the body's immune response directly against the tumor.3591011

Research Team

WC

William Curry, MD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

This trial is for adults with recurrent glioblastoma, a type of brain tumor. Participants must have had prior radiation, measurable disease, and be able to undergo an MRI. They should not have other ongoing serious illnesses or a history of certain cancers within the last 5 years (with some exceptions). Adequate organ function and agreement to use contraception are required.

Inclusion Criteria

My cancer has returned for the first time and I've had radiation before.
My cancer has returned or worsened for the first time and I've had radiation before.
I expect to take 4 mg or less of dexamethasone daily at the start of my CAR-v3-TEAM-E treatment.
See 16 more

Exclusion Criteria

I have received treatments targeting EGFRvIII before.
I've completed most of my radiation therapy without using temozolomide before getting CARv3-TEAM-E Infusion.
I am breastfeeding and receiving CARv3-TEAM-E treatment.
See 14 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Safety Run-In

Participants receive 1 infusion of CARv3-TEAM-E, with staggered enrollment and evaluation for dose-limiting toxicities

Up to 6 months
1 visit (in-person)

Treatment

Participants receive CARv3-TEAM-E T Cells weekly for 6 doses

6 weeks
6 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 years
Regular follow-up visits

Long-term Follow-up

Participants are monitored for long-term safety and survival outcomes

Up to 15 years

Treatment Details

Interventions

  • CARv3-TEAM-E T Cells
Trial Overview The study is testing CARv3-TEAM-E T cells to find the best dose for treating glioblastoma. These are modified immune cells designed to target and destroy cancer cells in patients who've seen their cancer return after initial treatment.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Safety Run-In PhaseExperimental Treatment1 Intervention
* Participant enrollment will be staggered by 30 days for up to 3 participants. * Participants will receive 1 infusion of CARv3-TEAM-E. * Phase will be expanded up to 6 participants if any Dose-Limiting Toxicities DLTs occur. * After all participants have been enrolled, there will be an evaluation made by the Data Safety Monitoring Board (DSMB) and the FDA to determine the safety of enrollment into additional arms.
Group II: Arm 3: Recurrent GBM, EGFRvIII NegativeExperimental Treatment1 Intervention
* Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw. * CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36. * Participants will be followed for 2 years post-treatment.
Group III: Arm 2: Newly Diagnosed GBM, EGFRvIII PositiveExperimental Treatment1 Intervention
* Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw. * CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36. * Participants will be followed for 2 years post-treatment.
Group IV: Arm 1: Recurrent Glioblastoma (GBM), EGFRvIII PositiveExperimental Treatment1 Intervention
* Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw. * CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36. * Participants will be followed for 2 years post-treatment.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Marcela V. Maus, M.D.,Ph.D.

Lead Sponsor

Trials
6
Recruited
110+

Findings from Research

CAR-T cell therapy is now an approved treatment for relapsed/refractory B-cell malignancies and is gaining attention for its potential application in solid tumors, particularly those that are immunologically 'cold' like glioblastoma.
This therapy works by genetically engineering a patient's own T cells to target tumor-associated antigens, which may help overcome the challenges posed by the hostile tumor microenvironment, although research in solid tumors is still in its early stages.
Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma.Brown, MP., Ebert, LM., Gargett, T.[2021]
CAR T-cell therapy not only targets tumors directly but also activates the body's own immune system, enhancing the response against glioblastoma (GBM) by promoting T-cell memory and activating myeloid cells.
The effectiveness of CAR T-cell therapy in GBM is significantly linked to IFNγ signaling, which helps remodel the tumor microenvironment to support stronger antitumor immune responses.
IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity.Alizadeh, D., Wong, RA., Gholamin, S., et al.[2022]
CAR T-cell therapy, which involves modifying a patient's own T cells to target cancer cells, has shown promising safety and feasibility in treating glioblastoma, a type of brain cancer, despite the challenges associated with this disease.
Some patients with glioblastoma have experienced signs of efficacy from CAR T-cell therapy, indicating potential for this treatment approach, even though significant barriers to effective T-cell function remain.
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.Bagley, SJ., Desai, AS., Linette, GP., et al.[2019]

References

Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. [2021]
IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. [2022]
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. [2019]
First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose. [2022]
Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives. [2021]
Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis. [2023]
CAR T Cells Infiltrate Brain, Target Tumors. [2018]
Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. [2021]
PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. [2023]
CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement. [2023]